Featured Publications
Association of renalase with clinical outcomes in hospitalized patients with COVID-19
Safdar B, Wang M, Guo X, Cha C, Chun HJ, Deng Y, Dziura J, El-Khoury JM, Gorelick F, Ko AI, Lee AI, Safirstein R, Simonov M, Zhou B, Desir GV. Association of renalase with clinical outcomes in hospitalized patients with COVID-19. PLOS ONE 2022, 17: e0264178. PMID: 35259186, PMCID: PMC8903289, DOI: 10.1371/journal.pone.0264178.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsRenalase levelsIntensive care unit admissionHospitalized COVID-19 patientsMean age 64 yearsCOVID-19Cox proportional hazards modelCare unit admissionPrimary composite outcomeRetrospective cohort studyUse of vasopressorsSevere COVID-19IL-6 levelsAge 64 yearsRisk of deathCOVID-19 subjectsInitial disease severityProportional hazards modelCOVID-19 diseasePlasma renalaseUnit admissionICU admissionCohort studyComposite outcomeCytokine levels
2024
Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023
DeCuir J, Surie D, Zhu Y, Lauring A, Gaglani M, McNeal T, Ghamande S, Peltan I, Brown S, Ginde A, Steinwand A, Mohr N, Gibbs K, Hager D, Ali H, Frosch A, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Mosier J, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Rhoads J, Swan S, Johnson C, Lewis N, Ellington S, Dawood F, McMorrow M, Self W, Network F. Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023. Influenza And Other Respiratory Viruses 2024, 18: e70027. PMID: 39496339, PMCID: PMC11534416, DOI: 10.1111/irv.70027.Peer-Reviewed Original ResearchConceptsCOVID-19-associated hospitalizationIn-hospital outcomesVaccine effectivenessMonovalent dosesAbsolute VETest-negative case-control designInvasive mechanical ventilationCOVID-19 vaccineMultivariate logistic regressionSevere COVID-19Case patientsCase-control designControl patientsMechanical ventilationUnvaccinated patientsPatientsMonovalent vaccineCOVID-19-like illnessDoseCOVID-19 vaccine effectivenessBivalent vaccineLogistic regressionAdmission dateVaccineHospitalSeverity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults
Surie D, Yuengling K, DeCuir J, Zhu Y, Lauring A, Gaglani M, Ghamande S, Peltan I, Brown S, Ginde A, Martinez A, Mohr N, Gibbs K, Hager D, Ali H, Prekker M, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Leis A, Khan A, Hough C, Bender W, Duggal A, Bendall E, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Mosier J, Safdar B, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Swan S, Johnson C, Lwin C, Lewis N, Ellington S, McMorrow M, Martin E, Self W. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Network Open 2024, 7: e244954. PMID: 38573635, PMCID: PMC11192181, DOI: 10.1001/jamanetworkopen.2024.4954.Peer-Reviewed Original ResearchConceptsInvasive mechanical ventilationRespiratory syncytial virusSeverity of RSV diseaseInfluenza diseaseVaccinated patientsIn-hospital deathUnvaccinated patientsRSV diseaseSyncytial virusClinical decision-makingComposite of invasive mechanical ventilationOutcome of invasive mechanical ventilationSeverity of respiratory syncytial virusLaboratory-confirmed respiratory syncytial virusHospitalized US adultsInfluenza vaccination statusVaccination statusAcute respiratory illnessMultivariate logistic regressionCenters for Disease Control and PreventionSeverity of COVID-19Disease Control and PreventionInfluenza infectionInfluenza severityClinical outcomesInterim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024
DeCuir J, Payne A, Self W, Rowley E, Dascomb K, DeSilva M, Irving S, Grannis S, Ong T, Klein N, Weber Z, Reese S, Ball S, Barron M, Naleway A, Dixon B, Essien I, Bride D, Natarajan K, Fireman B, Shah A, Okwuazi E, Wiegand R, Zhu Y, Lauring A, Martin E, Gaglani M, Peltan I, Brown S, Ginde A, Mohr N, Gibbs K, Hager D, Prekker M, Mohamed A, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Chang S, Mallow C, Kwon J, Exline M, Columbus C, Vaughn I, Safdar B, Mosier J, Harris E, Casey J, Chappell J, Grijalva C, Swan S, Johnson C, Lewis N, Ellington S, Adams K, Tenforde M, Paden C, Dawood F, Fleming-Dutra K, Surie D, Link-Gelles R, Collaborators C, Collaborators C, Ghamande S, Gottlieb R, McNeal T, Raver C, Bender W, Fletcher L, Heaton P, Kane S, McEvoy C, Thapa S, Vazquez-Benitez G, Frosch A, Lamerato L, Ramesh M, Arnofer J, Ali H, Hopkins J, Crane B, Dandamudi P, Goddard K, Hansen J, Timbol J, Zerbo O, Allen K, Duszynski T, Fadel W, Rogerson C, Qadir N, Chavez C, Doyle B, Mayer D, Rao S, Rivas C, Johnson N, Baughman A, Lwin C, Rhoads J, Womack K, Dunne M, Ciesla A, Mak J, Najdowski M, Ray C. Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024. MMWR Morbidity And Mortality Weekly Report 2024, 73: 180-188. PMID: 38421945, PMCID: PMC10907041, DOI: 10.15585/mmwr.mm7308a5.Peer-Reviewed Original ResearchConceptsVaccine effectivenessEmergency departmentCOVID-19 vaccineCDC's Advisory CommitteeCOVID-19-associated hospitalizationUrgent careCOVID-19 vaccine dosesImmunocompetent adultsMedian intervalCase-control designVE estimatesVaccine doseImmunization PracticesTest-negativeSevere diseaseCDC recommendationsDoseVaccineHospitalVE networkCOVID-19CDCMonthsAdvisory CommitteeDays
2023
Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023
Surie D, Yuengling K, DeCuir J, Zhu Y, Gaglani M, Ginde A, Talbot H, Casey J, Mohr N, Ghamande S, Gibbs K, Files D, Hager D, Ali H, Prekker M, Gong M, Mohamed A, Johnson N, Steingrub J, Peltan I, Brown S, Leis A, Khan A, Hough C, Bender W, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Lauring A, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Halasa N, Chappell J, Grijalva C, Baughman A, Rice T, Womack K, Han J, Swan S, Mukherjee I, Lewis N, Ellington S, McMorrow M, Martin E, Self W, Network I. Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years — IVY Network, 20 U.S. States, February 2022–May 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 1083-1088. PMID: 37796753, PMCID: PMC10564326, DOI: 10.15585/mmwr.mm7240a2.Peer-Reviewed Original ResearchConceptsHigh-flow nasal cannulaInvasive mechanical ventilationRSV disease severityNoninvasive ventilationDisease severityCOVID-19Intensive care unit admissionRespiratory syncytial virus vaccinationOlder adultsLaboratory-confirmed RSVCare unit admissionAcute respiratory illnessFlow oxygen therapyMultivariable logistic regressionCDC's Advisory CommitteeRespiratory syncytial virusSARS-CoV-2Advisory CommitteeUnit admissionICU admissionImmunization PracticesRSV vaccinationVirus vaccinationAdults AgedInfluenza severityRenin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19
Self W, Shotwell M, Gibbs K, de Wit M, Files D, Harkins M, Hudock K, Merck L, Moskowitz A, Apodaca K, Barksdale A, Safdar B, Javaheri A, Sturek J, Schrager H, Iovine N, Tiffany B, Douglas I, Levitt J, Busse L, Ginde A, Brown S, Hager D, Boyle K, Duggal A, Khan A, Lanspa M, Chen P, Puskarich M, Vonderhaar D, Venkateshaiah L, Gentile N, Rosenberg Y, Troendle J, Bistran-Hall A, DeClercq J, Lavieri R, Joly M, Orr M, Pulley J, Rice T, Schildcrout J, Semler M, Wang L, Bernard G, Collins S, Becker R, del Zoppo G, Henke P, Holubkov R, Johnson M, Kerr K, Lipman H, Lurie F, Pitt B, Vesely S, Fleg J, Aamodt D, Ayers J, Clark D, Collins J, Cook M, Dixon S, Graves J, Jordan C, Lindsell C, Lopez I, McKeel D, Orozco D, Prato N, Qi A, Qutab M, Stoughton C, Vermillion K, Walsh K, Winchell S, Young T, Franklin R, Wagner E, Walther T, Demitrack M, Johnson J, Walsh R, Bales B, Miller K, Torr D, Barot H, Landreth L, LaRose M, Parks L, Teixeira J, Cardenas S, Ceniceros J, Cunningham A, Kunkel S, Lovato D, Zimmerman B, Nguyen T, Zeger W, Nichols H, Wiedel N, Javaheri A, Stilinovic S, Brokowski C, Lu J, Solberg M, Lee D, Roach K, Tiffany B, Tanner C, Taylor A, Zumbahl J, Syed A, Mason J, Jackson P, Coleman R, Haughey H, Cherabuddi K, James N, Wakeman R, Duncan C, Montero C, Rogers A, Wilson J, Vojnik R, Perez C, Wyles D, Hiller T, Oakes J, Garcia A, Gong M, Mohamed A, Andrea L, Nair R, Nkemdirim W, Lopez B, Boujid S, Torres M, Garcia O, Martinez F, Baduashvili A, Bastman J, Chauhan L, Douin D, Finck L, Licursi A, ten Lohuis C, Zhang S, Bender W, Tovar S, Hayes S, Kurtzman N, Rosseto E, Scaffidi D, Shapiro N, Pak J, Allada G, Briceno G, Peña J, Oh M, Ali H, Beselman S, Eby Y, Klimov V, Hite R, Tanzeem H, Droege C, Winter J, Jackman S, Caudill A, Bayoumi E, Pascual E, Chen P, Mucha S, Thiruchelvam N, Siuba M, Mehkri O, Driver B, Hendrickson A, Kaus O, Ontiveros C, Riehm A, Laudun S, Hudock D, Ensley C, Shaner V, Gentile N, Isenberg D, Reimer H, Cincola P, Harris E, Callahan S, Yamane M, Barrios M, Desai N, Bharara A, Keller M, Majumder P, Dohe C, D’Armiento J, Goldklang M, Wagener G, Fonseca L, Valezquez-Sanchez I, Johnson N, Petersen E, Fuentes M, Newton M, Gundel S, Srinivasan V, Steel T, Robinson B. Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19. JAMA 2023, 329: 1170-1182. PMID: 37039791, PMCID: PMC10091180, DOI: 10.1001/jama.2023.3546.Peer-Reviewed Original ResearchConceptsAngiotensin II type 1 receptorII type 1 receptorRenin-angiotensin systemSevere COVID-19Type 1 receptorCause mortalityRAS agentsRAS modulationPlacebo groupAngiotensin IIIntravenous infusionOdds ratioSafety outcomesCOVID-19Renin-angiotensin system modulationSARS-CoV-2 infectionAcute COVID-19Key secondary outcomesAction of angiotensinKidney replacement therapySupplemental oxygen useCOVID-19 pathophysiologyContinuous intravenous infusionLast followSecondary outcomes
2021
Sex- or Gender-specific Differences in the Clinical Presentation, Outcome, and Treatment of SARS-CoV-2
Wolfe J, Safdar B, Madsen TE, Sethuraman KN, Becker B, Greenberg MR, McGregor AJ. Sex- or Gender-specific Differences in the Clinical Presentation, Outcome, and Treatment of SARS-CoV-2. Clinical Therapeutics 2021, 43: 557-571.e1. PMID: 33583576, PMCID: PMC7833665, DOI: 10.1016/j.clinthera.2021.01.015.Peer-Reviewed Original ResearchConceptsImmunologic responseBody's immunologic responseCOVID-19 presentationComplications of infectionSARS-CoV-2Influence of hormonesGender-specific differencesClinical presentationLaboratory presentationOutcomesSex differencesSexBody responseInfectionTreatmentPresentationGender differencesResponseComplicationsDifferencesHormonePrevention